Answers are grounded in this paper and cite their sources.
This study investigates the long-term impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i)on body composition in individuals with type 2 diabetes (T2D), with a focus on age-related differences. We evaluated changes in body mass index (BMI), body fat percentage, skeletal muscle mass and skeletal muscle mass index (SMI) over 4.4 years on average. This retrospective, single-center clinical cohort study utilized electronic medical records from the University of Tokyo Hospital. 70 people with T2D treated with SGLT2i for more than two years were included. Body compositions were assessed using bioelectrical impedance analysis (BIA) at three time points: before SGLT2i therapy, 1 year after SGLT2 therapy initiation and the latest along with SGLT2i therapy. During the 4.4-year average treatment period, significant reductions were observed in BMI (30.5 to 29.1, p < 0.0001) and skeletal muscle mass (30.3 kg to 29.0 kg, p < 0.0001). ΔBMI was positively correlated with ΔBody fat percentage and ΔSkeletal muscle mass (all p < 0.0001). Age-stratified analysis showed that in younger individuals, ΔSkeletal muscle mass was significantly associated with both treatment duration and ΔBMI. In contrast, older individuals showed a weaker correlation between ΔSkeletal muscle mass and ΔBMI, and experienced significant muscle mass decline at an earlier point. SGLT2i are effective in managing T2D and reducing BMI and body fat. However, careful monitoring of body composition is crucial, especially in older individuals, to mitigate the risk of sarcopenia and maintain overall health. • This retrospective cohort study evaluated age-related differences in body composition changes during long-term SGLT2 inhibitor therapy in individuals with type 2 diabetes. • Reduction in skeletal muscle mass was observed in both age groups, with no significant difference in the rate of decline between younger and older individuals. • In older individuals, skeletal muscle mass tended to decrease earlier and changes were less clearly reflected in BMI, underscoring the importance of early monitoring to prevent sarcopenia.
No takes yet. Share an insight, caveat, or question.
Aoyama et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: